Objective: To assess the impact of sepsis classification and multidrug-resistance status on outcome in patients receiving appropriate initial antibiotic therapy. Design: A retrospective cohort study. Setting: Barnes-Jewish Hospital, a 1,250-bed teaching hospital. Patients: Individuals with Enterobacteriaceae sepsis, severe sepsis, and septic shock who received appropriate initial antimicrobial therapy between June 2009 and December 2013. Interventions: Clinical outcomes were compared according to multidrug-resistance status, sepsis classification, demographics, severity of illness, comorbidities, and antimicrobial treatment. Measurements and Main Results: We identified 510 patients with Enterobacteriaceae bacteremia and sepsis, severe sepsis, or septic shock. Sixty-seven patients (13.1%) were nonsurvivors. Mortality increased significantly with increasing severity of sepsis (3.5%, 9.9%, and 28.6%, for sepsis, severe sepsis, and septic shock, respectively; p < 0.05). Time to antimicrobial therapy was not significantly associated with outcome. Acute Physiology and Chronic Health Evaluation II was more predictive of mortality than ageadjusted Charlson comorbidity index. Multidrug-resistance status did not result in excess mortality. Length of ICU and hospital stay increased with more severe sepsis. In multivariate logistic regression analysis, African-American race, sepsis severity, Acute Physiology and Chronic Health Evaluation II score, solid-organ cancer, cirrhosis, and transfer from an outside hospital were all predictors of mortality. Conclusions: Our results support sepsis severity, but not multidrug-resistance status as being an important predictor of death when all patients receive appropriate initial antibiotic therapy. Future sepsis trials should attempt to provide appropriate antimicrobial therapy and take sepsis severity into careful account when determining outcomes. (Crit Care Med 2015; 43:1580-1586 Key Words: multidrug resistance; sepsis mortality I nappropriate initial antimicrobial therapy leads to higher mortality in patients with severe sepsis or septic shock (1-5). Multidrug-resistant (MDR) pathogens are prone to treatment with initial inappropriate antimicrobial therapy, but whether drug resistance alone increases mortality in the setting of appropriate therapy is unclear (6-10). The presence of severe sepsis with organ failure and shock requiring vasopressor support are predictors of greater mortality in populations with variable rates of appropriate antimicrobial therapy (1, (11) (12) (13) (14) (15) (16) . Neither the presence of severe sepsis or shock nor MDR as predictors of mortality has been studied in a cohort of patients with sepsis who all received appropriate initial antimicrobial therapy. Our primary goal was to compare 30-day all-cause mortality among patients with sepsis, severe sepsis, and septic shock treated with appropriate initial antimicrobial therapy to more directly assess the impact of sepsis severity on outcome. Our secondary objective was to examine the impact of MDR on mortality in the same cohort. We selected only patients with Enterobacteriaceae bacteremia for two reasons: 1) the prevalence of MDR Enterobacteriaceae infections is increasing worldwide (17-21) and 2) for a homogeneous population in order to minimize pathogen-related confounders. 
Definitions
Patients were considered to have a bloodstream infection due to Enterobacteriaceae if any blood culture obtained within 48 hours of developing sepsis, severe sepsis, or septic shock were positive for Escherichia coli, Klebsiella Patients were required to have at least one of the following ICD-9 codes: 995.91 (sepsis), 995.92 (severe sepsis), 038 (septicemia), 790.7 (bacteremia nosocomial), or 785.52 (septic shock). For patients to be included in the septic shock group, they had to receive blood pressure support with any of the following medications within 24 hours of positive blood culture: norepinephrine, phenylephrine, epinephrine, dopamine, dobutamine, or vasopressin. All patients had to receive appropriate initial antibiotic therapy, defined as antibiotics that had in vitro activity against the cultured organism (and were not single-agent aminoglycosides), that was administered within 12 hours of when a positive blood culture was drawn and continued for at least 24 hours. For extended-spectrum β-lactamaseproducing organisms, initial use of a carbapenem was required to be classified as appropriate treatment. Antimicrobial susceptibilities were determined using disc diffusion methodology. MDR was defined as nonsusceptibility to at least one antimicrobial agent from at least three different antimicrobial classes (23) . Appropriate antibiotics administered up to 12 hours before positive blood cultures were drawn were considered to have a time of administration of 0 minute. Patients with pathogens resistant to ampicillin were not considered to have received appropriate therapy if they received ampicillin/sulbactam.
Only the first episode of bacteremia during a hospitalization was considered. Patients who had an episode of bacteremia during their hospitalization prior to Enterobacteriaceae bacteremia were excluded (only two cases, one with Staphylococcus epidermidis and another with Enterococcus). The following organisms were considered contaminants if not recultured within 72 hours: coagulase-negative Staphylococci, Corynebacterium, Propionibacterium acnes, or Viridans group Streptococcus. Patients were excluded if they were under 18 years or if they had a blood culture positive for more than one organism. All patients who did not receive antibiotics within 12 hours of when positive blood cultures were drawn were excluded. Discharge on hospice was considered a mortality equivalent. All patients discharged on hospice were considered to expire at the time of hospital discharge. In the number of procedures analysis, codes for vasopressors and mechanical ventilation were not included in the final tally. Blood product administration was considered a procedure, but only one instance was counted. Otherwise, all ICD-9 procedure codes were considered in the number of procedures analysis. LOS was calculated from time a positive blood culture was drawn. Patients who never required ICU admission were considered to have an ICU stay length of 0 day. Healthcare exposure was defined as chemotherapy within the prior 30 days, residence in a nursing home or other long-term care facility, hospitalization in an acute care hospital for two or more days within the prior 90 days, or attendance at a hospital or hemodialysis clinic within the prior 30 days.
Thirty-day mortality was assessed using the BJC Healthcare informatics database. Barnes-Jewish Hospital serves as the main teaching institution for BJC Healthcare, a large integrated healthcare system of both inpatient and outpatient care. The system includes a total of 13 hospitals in a compact geographic region surrounding and including St. Louis, MO. Persons treated within this healthcare system are, in nearly all cases, readmitted to one of the system's participating hospitals or evaluated in a BJC Healthcare outpatient practice. If a patient who receives healthcare in the system presents to a nonsystem hospital, he/ she is often transferred back into the integrated system because of issues of insurance coverage. Death certificate records and autopsy reports are included in the informatics database. All data were derived from the informatics database provided by the Center for Clinical Excellence, BJC HealthCare.
Statistical Analysis
Thirty-day all-cause mortality was compared between the sepsis, severe sepsis, and septic shock groups. Univariate analysis was performed by chi-square or Fischer exact test where appropriate for categorical values. Student t test or Mann-Whitney U test was used where appropriate for continuous variables. Continuous variables were reported as means with sds. Categorical data were expressed as frequencies. A p value of less than 0.05 was considered significant. Multivariate analysis comparing survivors and nonsurvivors was used to determine risk factors for mortality. Factors associated with mortality in univariate analysis (p < 0.20) were entered into a multivariate logistic regression analysis to determine odds ratios for mortality. All variables entered into the model were assessed for collinearity, and interaction terms were tested. Goodness-of-fit was assessed via the Hosmer-Lemeshow c-statistic. All tests were two-tailed. All analysis was done using SPSS v22 (IBM Corp., Armonk, NY).
RESULTS
Five hundred ten patients with sepsis, severe sepsis, or septic shock due to Enterobacteriaceae met the inclusion criteria. There were no cases with multiple episodes of Enterobacteriaceae bacteremia identified. Baseline characteristics of the patients are listed in Table 1 . Patients with septic shock had the greatest 
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APACHE II scores and need for mechanical ventilation. Time to appropriate initial antibiotic therapy was shortest for patients with septic shock. The distribution of pathogens is shown in Table 2 . There was no significant difference in pathogen distribution according to sepsis classification. The most common organism was E. coli. There were no significant differences in the proportion of individual pathogens between survivors and nonsurvivors (data not shown). Among the 510 cases, 99 (19.4%) met MDR criteria. As the severity of sepsis increased, so did the LOS, ICU LOS, number of procedures, and mortality (Table 3) . Kaplan-Meier curves confirmed that increasing sepsis severity was associated with greater 30-day mortality (Fig. 1) . Total LOS, prevalence of MDR pathogens, and number of procedures performed were not significantly different between the survivors and nonsurvivors. Nonsurvivors had significantly longer ICU LOS (Table 3) . Age, Charlson Comorbidity Index, APACHE II, leukemia, cirrhosis, solid-organ malignancy, origin from an outside hospital, pulmonary source of infection, and congestive heart failure were significantly different between survivors and nonsurvivors in univariate analysis (Table 1 ). Time to antibiotic therapy after a positive blood culture was drawn did not differ between survivors and nonsurvivors. In multivariate analysis, patients who died were more likely to be African-American, 
DISCUSSION
We found that sepsis severity predicted mortality among patients receiving appropriate initial antimicrobial therapy. The presence of MDR did not appear to influence outcome when the initial therapy was appropriate for the causative pathogen. Interestingly, patients with septic shock had a significantly shorter time to appropriate antibiotic administration than patients with sepsis alone, but still had significantly higher mortality. These results suggest that appropriate antimicrobials are insufficient to completely overcome the systemic calamity associated with septic shock. However, appropriate therapy is still crucial, as suggested by the low overall mortality in our cohort (13.1%) compared to studies with varying levels of appropriate empiric antimicrobial therapy (24) . In the future, clinical trials should strive to provide appropriate antimicrobial therapy and take sepsis severity into careful account when determining outcomes. Unsurprisingly, as sepsis severity increased, LOS, ICU LOS, and number of procedures significantly increased. Length of stay was not statistically different between survivors and nonsurvivors, but this is likely a result of hospital stays truncated by death.
MDR was not statistically different when comparing sepsis severity groups nor between survivors and nonsurvivors. Past studies have posited that the presence of MDR leads to worse outcomes and possibly even conveys increased virulence (10, 25) . Prior studies have shown that MDR is a risk factor for mortality in the setting of inappropriate initial antimicrobial therapy (26) . Our study population included only patients who received appropriate antimicrobial therapy; we found no evidence of increased mortality due to MDR. Our data demonstrate that this increased mortality is negated with appropriate and timely antimicrobial therapy. The current paucity of agents to treat MDR pathogens limits our ability to administer appropriate initial therapy for many drugresistant bacteria. Fortunately, there are quality improvement measures, improving molecular technologies, and new antimicrobials in the pipeline that provide hope to stay in step with increasing drug resistance (27) (28) (29) (30) (31) . African-American race as a risk factor for mortality is likely an unfortunate marker for racial disparities in healthcare rather than a genetic predisposition. Transfer from an outside hospital may increase mortality because of the high level of acuity of patients transferred from institutions with limited resources. Increasing APACHE II scores, underlying malignancy, and cirrhosis have previously been shown to be independent risk factors for mortality in sepsis and reflect acute and chronic illness severity (1, 8, 26, 32) .
Our study is limited in several ways. The retrospective nature of the study makes it difficult to elucidate possible confounders that could have biased the outcome measures. This was a single-center study, and results may not be generalizable to other centers. However, the lack of increased mortality with MDR pathogens should be applicable to other cohorts that have received appropriate therapy. We did not study outcomes in patients with Gram-positive infections or non-Enterobacteriaceae Gram-negative infections. It is possible that there would be different results in these populations and this is an area ripe for future studies. Another limitation is the method of determining 30-day mortality. It is possible that some patients died outside of the BJC Healthcare network and that we were unable to capture their mortality status. However, it is unlikely that this would have influenced our results given the clear signal observed between sepsis severity and outcome. We are also limited by a lack of antimicrobial minimum inhibitory concentration (MIC) data to determine if the administered antibiotics were therapeutic at a given MIC. However, our microbiology laboratory uses well-validated disc diffusion methodology to determine antimicrobial susceptibilities. Utilizing susceptibility data, our pharmacy uses an antimicrobial control program and reviews all antimicrobial orders as previously described (8) , which minimizes inadequate therapy.
For ease of data collection and interpretation, we focused on culture-positive patients with sepsis. We recognize that historically, culture-negative patients fare better than their culture-positive counterparts. However, assessing antimicrobial appropriateness according to our definition was impractical without culture data. With improving molecular technologies, the number of culture-negative patients will likely decrease, thereby increasing the spectrum of patients who can be assessed for antimicrobial appropriateness. We are also limited in the assessment of differential outcomes based on specific pathogens due to the low frequency of infection with pathogens other than E. coli and K. pneumoniae.
In conclusion, severity of sepsis is an important predictor of mortality, even in patients who all receive appropriate initial antimicrobial therapy. In patients who receive appropriate initial therapy, we found no difference in outcome based on time to appropriate therapy, as long as it was administered within 12 hours after a positive culture was drawn. Our results will assist in the interpretation of outcomes in sepsis clinical trials. Additionally, physicians will now be better able to prognosticate for patient families with evidence to support the claim that the presence of shock quadruples the risk of death as compared with its absence, even in the setting of appropriate antimicrobials. Our findings suggest that appropriate initial antimicrobial therapy eliminates the impact of MDR on mortality, providing another impetus for improved diagnostics and antimicrobials for drug-resistant pathogens. Future studies can assess similar outcomes in patients with Gram-positive or Gram-negative non-Enterobacteriaceae sepsis. Odds ratio for death between two groups (sepsis and severe sepsis, severe sepsis, and septic shock). When comparing sepsis and septic shock, the odds ratio is multiplied by two for each degree of separation. Hosmer-Lemeshow c-statistic = 0.457.
